JS015 / Shanghai Junshi Biosci - LARVOL DELTA

A Phase 2 Study Evaluating the Safety and Efficacy of JS207 With or Without JS015 in Combination With Chemotherapy in Patients With Colorectal Cancer (clinicaltrials.gov) - P2 | N=60 | Recruiting | Sponsor: Shanghai Junshi Bioscience Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Colorectal Cancer • Oncology • Solid Tumor

Efficacy and safety of JS015 (an anti-dickkopf-1 antibody) in combination with standard of care in patients with gastrointestinal cancers (AACR 2025) - P1/2, P2 | "Here, we report the preliminary efficacy and safety data of JS015 in combination with standard of care in gastrointestinal patients from JS015-002 study (NCT06139211) and 2 IITs (ChiCTR2400091501 and ChiCTR2400088962) conducted in China. Patients with colorectal cancer that were not systematically treated (1L-CRC) or who had progressed after treatment with fluorouracil-based regimen (2L-CRC) received JS015 600 mg (intravenously) plus bevacizumab and chemotherapy, once every 2 weeks or 3 weeks, depending on chemotherapy schedules. Patients with gastric cancer that were not systematically treated (1L-GC) received JS015 600 mg plus toripalimab and chemotherapy, once every 3 weeks... JS015 combination therapy showed encouraging anti-tumor activities in patients with CRC and GC, with a favorable safety profile, supporting further investigations in a large population of patients with gastrointestinal carcinomas."

Clinical • Combination therapy • Late-breaking abstract • Colorectal Cancer • Gastric Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor • DKK1

A Phase 2 Study Evaluating the Safety and Efficacy of JS207 With or Without JS015 in Combination With Chemotherapy in Patients With Colorectal Cancer (clinicaltrials.gov) - P2 | N=60 | Not yet recruiting | Sponsor: Shanghai Junshi Bioscience Co., Ltd.

New P2 trial • Colorectal Cancer • Oncology • Solid Tumor

JS015 Combined Therapy in Gastrointestinal Tumors: A Multi-Cohort, Multi-Center, Exploratory Clinical Study (ChiCTR) - P2 | N=56 | Sponsor: Shanghai East Hospital; Shanghai East Hospital

New P2 trial • Colon Adenocarcinoma • Colon Cancer • Colorectal Adenocarcinoma • Esophageal Cancer • Gastric Adenocarcinoma • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Gastrointestinal Cancer • Gastrointestinal Disorder • Oncology • Rectal Adenocarcinoma • Solid Tumor • HER-2

A Phase Ib/II Study Of JS015 Combination Therapy in Advanced Solid Tumors (clinicaltrials.gov) - P1/2 | N=186 | Recruiting | Sponsor: Shanghai Junshi Bioscience Co., Ltd. | Not yet recruiting ➔ Recruiting | Trial completion date: Apr 2026 ➔ Jan 2026

Enrollment open • Metastases • Trial completion date • Gastric Cancer • Oncology • Solid Tumor

JS015 in combination with chemotherapy and bevacizumab as second-line treatment in advanced colorectal cancer (ChiCTR) - P2 | N=37 | Not yet recruiting | Sponsor: Shanghai East Hospital; Shanghai East Hospital

Combination therapy • Metastases • New P2 trial • Colon Cancer • Colorectal Adenocarcinoma • Colorectal Cancer • Oncology • Solid Tumor

FD-IMPACT: Newly Emerging Immunotherapy for Pancreatic Cancer Treatment (clinicaltrials.gov) - P1/2 | N=117 | Not yet recruiting | Sponsor: Fudan University

New P1/2 trial • Gastrointestinal Cancer • Hepatology • Oncology • Pancreatic Cancer • Solid Tumor

A Phase Ib/II Study Of JS015 Combination Therapy in Advanced Solid Tumors (clinicaltrials.gov) - P1/2 | N=186 | Not yet recruiting | Sponsor: Shanghai Junshi Bioscience Co., Ltd.

Combination therapy • Metastases • New P1/2 trial • Gastric Cancer • Oncology • Solid Tumor

A Phase I Study Of JS015 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=114 | Recruiting | Sponsor: Shanghai Junshi Bioscience Co., Ltd.

Metastases • New P1 trial • Oncology • Solid Tumor